

Julian Segura

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/9420802/julian-segura-publications-by-year.pdf>

Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

182 papers	8,097 citations	34 h-index	88 g-index
213 ext. papers	10,648 ext. citations	4.2 avg, IF	5.28 L-index

#	Paper	IF	Citations
182	Antihypertensive therapy and short-term blood pressure variability. <i>Journal of Hypertension</i> , 2021 , 39, 349-355	1.9	1
181	Kidneys also speak Spanish. <i>Nefrologia</i> , 2021 , 41, 225-226	1.5	4
180	2021 Spanish Society of Hypertension position statement about telemedicine. <i>Hipertension Y Riesgo Vascular</i> , 2021 , 38, 186-196	0.5	0
179	TCA Cycle and Fatty Acids Oxidation Reflect Early Cardiorenal Damage in Normoalbuminuric Subjects with Controlled Hypertension. <i>Antioxidants</i> , 2021 , 10,	7.1	3
178	Early renal and vascular damage within the normoalbuminuria condition. <i>Journal of Hypertension</i> , 2021 , 39, 2220-2231	1.9	0
177	Kidneys also speak Spanish: Initiatives towards standardisation of our nephrology nomenclature. <i>Nefrologia</i> , 2021 , 42, 223-223	1.5	0
176	Differential metabolic profile associated with the condition of normoalbuminuria in the hypertensive population. <i>Nefrologia</i> , 2020 , 40, 439-445	0.4	2
175	Prevalence of office and ambulatory hypotension in treated hypertensive patients with coronary disease. <i>Hypertension Research</i> , 2020 , 43, 696-704	4.7	3
174	How do ultrafine particles in urban air affect ambulatory blood pressure?. <i>Journal of Hypertension</i> , 2020 , 38, 845-849	1.9	1
173	Differential metabolic profile associated with the condition of normoalbuminuria in the hypertensive population. <i>Nefrologia</i> , 2020 , 40, 440-445	1.5	2
172	Retraction: Banegas JR et al. Relationship between Clinic and Ambulatory Blood-Pressure Measurements and Mortality. N Engl J Med 2018;378:1509-20. <i>New England Journal of Medicine</i> , 2020 , 382, 786	59.2	4
171	Prognostic Relevance of Short-Term Blood Pressure Variability: The Spanish ABPM Registry. <i>Hypertension</i> , 2020 , HYPERTENSIONAHA11914508	8.5	1
170	Association of clinic and ambulatory heart rate parameters with mortality in hypertension. <i>Journal of Hypertension</i> , 2020 , 38, 2416-2426	1.9	6
169	Resistant hypertension: new insights and therapeutic perspectives. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2020 , 6, 188-193	6.4	4
168	Renal denervation for the treatment of resistant hypertension in Spain. The Flex-Spyral Registry. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2020 , 73, 615-622	0.7	
167	Denervaci3n renal para el tratamiento de la hipertensi3n arterial resistente en Espa3a. Registro Flex-Spyral. <i>Revista Espanola De Cardiologia</i> , 2020 , 73, 615-622	1.5	3
166	Variations in Circulating Active MMP-9 Levels During Renal Replacement Therapy. <i>Biomolecules</i> , 2020 , 10,	5.9	2

165	Frequency and Prognosis of Treated Hypertensive Patients According to Prior and New Blood Pressure Goals. <i>Hypertension</i> , 2019 , 74, 130-136	8.5	9
164	Association between renal dysfunction and metalloproteinase (MMP)-9 activity in hypertensive patients. <i>Nefrologia</i> , 2019 , 39, 184-191	0.4	4
163	Patient with White-Coat Hypertension. <i>Practical Case Studies in Hypertension Management</i> , 2019 , 1-10	0.1	
162	Patient with Masked Hypertension. <i>Practical Case Studies in Hypertension Management</i> , 2019 , 11-21	0.1	
161	Patient with Isolated Diurnal Hypertension. <i>Practical Case Studies in Hypertension Management</i> , 2019 , 23-32	0.1	
160	Patient with Isolated Nocturnal Hypertension. <i>Practical Case Studies in Hypertension Management</i> , 2019 , 33-42	0.1	
159	Patient with Resistant Hypertension. <i>Practical Case Studies in Hypertension Management</i> , 2019 , 53-65	0.1	
158	Patient with Pseudo-Resistant Hypertension. <i>Practical Case Studies in Hypertension Management</i> , 2019 , 67-74	0.1	
157	Patient with Drug-Induced Hypotension. <i>Practical Case Studies in Hypertension Management</i> , 2019 , 75-84	0.1	
156	ESC Council on hypertension position document on the management of hypertensive emergencies. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019 , 5, 37-46	6.4	68
155	Urine Haptoglobin and Haptoglobin-Related Protein Predict Response to Spironolactone in Patients With Resistant Hypertension. <i>Hypertension</i> , 2019 , 73, 794-802	8.5	2
154	Microalbuminuria and cardiorenal risk: old and new evidence in different populations. <i>F1000Research</i> , 2019 , 8,	3.6	5
153	Association between renal dysfunction and metalloproteinase (MMP)-9 activity in hypertensive patients. <i>Nefrologia</i> , 2019 , 39, 184-191	1.5	3
152	Blood pressure variability increases with advancing chronic kidney disease stage: a cross-sectional analysis of 16 546 hypertensive patients. <i>Journal of Hypertension</i> , 2018 , 36, 1076-1085	1.9	41
151	Relationship between Clinic and Ambulatory Blood-Pressure Measurements and Mortality. <i>New England Journal of Medicine</i> , 2018 , 378, 1509-1520	59.2	327
150	Prevalence of Masked Hypertension in Untreated and Treated Patients With Office Blood Pressure Below 130/80 mm Hg. <i>Circulation</i> , 2018 , 137, 2651-2653	16.7	25
149	Antihypertensive drug use in resistant and nonresistant hypertension and in controlled and uncontrolled resistant hypertension. <i>Journal of Hypertension</i> , 2018 , 36, 1563-1570	1.9	2
148	2018 ESC/ESH Guidelines for the management of arterial hypertension. <i>European Heart Journal</i> , 2018 , 39, 3021-3104	9.5	3698

147	Magnitude of Hypotension Based on Office and Ambulatory Blood Pressure Monitoring: Results From a Cohort of 5066 Treated Hypertensive Patients Aged 80 Years and Older. <i>Journal of the American Medical Directors Association</i> , 2017 , 18, 452.e1-452.e6	5.9	21
146	24-h pulse pressure cutoff point definition by office pulse pressure in a population of Spanish older hypertensive patients. <i>Journal of Hypertension</i> , 2017 , 35, 1011-1018	1.9	4
145	Clinic Versus Daytime Ambulatory Blood Pressure Difference in Hypertensive Patients: The Impact of Age and Clinic Blood Pressure. <i>Hypertension</i> , 2017 , 69, 211-219	8.5	20
144	Immune system deregulation in hypertensive patients chronically RAS suppressed developing albuminuria. <i>Scientific Reports</i> , 2017 , 7, 8894	4.9	11
143	Citric Acid Metabolism in Resistant Hypertension: Underlying Mechanisms and Metabolic Prediction of Treatment Response. <i>Hypertension</i> , 2017 , 70, 1049-1056	8.5	25
142	Prevalence and clinical characteristics of white-coat hypertension based on different definition criteria in untreated and treated patients. <i>Journal of Hypertension</i> , 2017 , 35, 2388-2394	1.9	28
141	Prevalence and Clinical Characteristics of Refractory Hypertension. <i>Journal of the American Heart Association</i> , 2017 , 6,	6	34
140	Progression of Renal Insufficiency in Patients with Essential Hypertension Treated with Renin Angiotensin Aldosterone System Blockers: An Electrocardiographic Correlation. <i>Diseases (Basel, Switzerland)</i> , 2017 , 5,	4.4	1
139	Rapid, Automated, and Specific Immunoassay to Directly Measure Matrix Metalloproteinase-9-Tissue Inhibitor of Metalloproteinase-1 Interactions in Human Plasma Using AlphaLISA Technology: A New Alternative to Classical ELISA. <i>Frontiers in Immunology</i> , 2017 , 8, 853	8.4	9
138	Kalirin and CHD7: novel endothelial dysfunction indicators in circulating extracellular vesicles from hypertensive patients with albuminuria. <i>Oncotarget</i> , 2017 , 8, 15553-15562	3.3	17
137	Urinary exosomes reveal protein signatures in hypertensive patients with albuminuria. <i>Oncotarget</i> , 2017 , 8, 44217-44231	3.3	23
136	Modification over time of pulse wave velocity parallel to changes in aortic BP, as well as in 24-h ambulatory brachial BP. <i>Journal of Human Hypertension</i> , 2016 , 30, 186-90	2.6	1
135	Hypertensive patients exhibit an altered metabolism. A specific metabolite signature in urine is able to predict albuminuria progression. <i>Translational Research</i> , 2016 , 178, 25-37.e7	11	19
134	Association Between High and Very High Albuminuria and Nighttime Blood Pressure: Influence of Diabetes and Chronic Kidney Disease. <i>Diabetes Care</i> , 2016 , 39, 1729-37	14.6	17
133	Role of matrix metalloproteinase-9 in chronic kidney disease: a new biomarker of resistant albuminuria. <i>Clinical Science</i> , 2016 , 130, 525-38	6.5	28
132	Office and ambulatory blood pressure control in hypertensive patients treated with different two-drug and three-drug combinations. <i>Clinical and Experimental Hypertension</i> , 2016 , 38, 409-14	2.2	0
131	Second denervation in a patient with resistant hypertension. <i>Clinical Research in Cardiology</i> , 2016 , 105, 880-3	6.1	1
130	Ambulatory blood pressure in hypertensive patients with inclusion criteria for the SPRINT trial. <i>Journal of the American Society of Hypertension</i> , 2016 , 10, 947-953.e5		19

129	Approaching to DM2 through sodium-glucose cotransporter-2: does it make sense?. <i>Medicina Clínica</i> , 2016 , 147 Suppl 1, 22-25	1	
128	Plasma Molecular Signatures in Hypertensive Patients With Renin-Angiotensin System Suppression: New Predictors of Renal Damage and De Novo Albuminuria Indicators. <i>Hypertension</i> , 2016 , 68, 157-66	8.5	14
127	Urinary alpha-1 antitrypsin and CD59 glycoprotein predict albuminuria development in hypertensive patients under chronic renin-angiotensin system suppression. <i>Cardiovascular Diabetology</i> , 2016 , 15, 8	8.7	21
126	Short-Term and Long-Term Reproducibility of Hypertension Phenotypes Obtained by Office and Ambulatory Blood Pressure Measurements. <i>Journal of Clinical Hypertension</i> , 2016 , 18, 927-33	2.3	26
125	From malignant hypertension to hypertension-MOD: a modern definition for an old but still dangerous emergency. <i>Journal of Human Hypertension</i> , 2016 , 30, 463-6	2.6	52
124	Hypotension based on office and ambulatory monitoring blood pressure. Prevalence and clinical profile among a cohort of 70,997 treated hypertensives. <i>Journal of the American Society of Hypertension</i> , 2016 , 10, 714-23		20
123	Ambulatory blood pressure monitoring in daily clinical practice - the Spanish ABPM Registry experience. <i>European Journal of Clinical Investigation</i> , 2016 , 46, 92-8	4.6	24
122	An update of the blockade of the renin angiotensin aldosterone system in clinical practice. <i>Expert Opinion on Pharmacotherapy</i> , 2015 , 16, 2283-92	4	19
121	Prediction of development and maintenance of high albuminuria during chronic renin-angiotensin suppression by plasma proteomics. <i>International Journal of Cardiology</i> , 2015 , 196, 170-7	3.2	16
120	Ethnic differences in the degree of morning blood pressure surge and in its determinants between Japanese and European hypertensive subjects: data from the ARTEMIS study. <i>Hypertension</i> , 2015 , 66, 750-6	8.5	69
119	Ambulatory Blood Pressures in Hypertensive Patients Treated With One Antihypertensive Agent: Differences Among Drug Classes and Among Drugs Belonging to the Same Class. <i>Journal of Clinical Hypertension</i> , 2015 , 17, 857-65	2.3	7
118	Reflections on two consensus documents about chronic kidney disease. <i>Nefrología</i> , 2015 , 35, 127-130	0.4	1
117	High prevalence of masked uncontrolled hypertension in people with treated hypertension. <i>European Heart Journal</i> , 2014 , 35, 3304-12	9.5	132
116	Nocturnal hypertension or nondipping: which is better associated with the cardiovascular risk profile?. <i>American Journal of Hypertension</i> , 2014 , 27, 680-7	2.3	78
115	Diuretics in the treatment of hypertension. Part 2: loop diuretics and potassium-sparing agents. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 605-21	4	39
114	Reply: contribution of the ABP-International study to the definition of night-time tachycardia. <i>Journal of Hypertension</i> , 2014 , 32, 2101	1.9	0
113	Development of albuminuria and enhancement of oxidative stress during chronic renin-angiotensin system suppression. <i>Journal of Hypertension</i> , 2014 , 32, 2082-91; discussion 2091	1.9	35
112	Long-term blockade of the renin-angiotensin system: an adequate evaluation is still needed. <i>Hypertension Research</i> , 2014 , 37, 701-2	4.7	1

111	Heart rate and heart rate variability in resistant versus controlled hypertension and in true versus white-coat resistance. <i>Journal of Human Hypertension</i> , 2014 , 28, 416-20	2.6	9
110	Usefulness of ambulatory blood pressure monitoring (ABPM) in daily clinical practice: Data from the Spanish ABPM registry. <i>Clinical and Experimental Pharmacology and Physiology</i> , 2014 , 41, 30-6	3	7
109	Night-time heart rate cut-off point definition by resting office tachycardia in untreated hypertensive patients: data of the Spanish ABPM registry. <i>Journal of Hypertension</i> , 2014 , 32, 1016-24; discussion 1024	1.9	5
108	Diuretics in the treatment of hypertension. Part 1: thiazide and thiazide-like diuretics. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 527-47	4	47
107	Spanish Society of Nephrology document on KDIGO guidelines for the assessment and treatment of chronic kidney disease. <i>Nefrologia</i> , 2014 , 34, 302-16	1.5	24
106	Dual neurohormonal intervention in CV disease: angiotensin receptor and Neprilysin inhibition. <i>Expert Opinion on Investigational Drugs</i> , 2013 , 22, 915-25	5.9	21
105	Management of resistant hypertension in a multidisciplinary unit of renal denervation: protocol and results. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2013 , 66, 364-70	0.7	
104	Differences between office and 24-hour blood pressure control in hypertensive patients with CKD: A 5,693-patient cross-sectional analysis from Spain. <i>American Journal of Kidney Diseases</i> , 2013 , 62, 285-94	7.4	72
103	Olmesartán con diuréticos o con antagonistas del calcio: ¿a qué perfil de paciente hipertenso?. <i>Hipertension Y Riesgo Vascular</i> , 2013 , 30, 16-20	0.5	
102	Manejo de la hipertensión resistente en una unidad multidisciplinaria de denervación renal: protocolo y resultados. <i>Revista Espanola De Cardiologia</i> , 2013 , 66, 364-370	1.5	14
101	Guidelines updates in the treatment of obesity or metabolic syndrome and hypertension. <i>Current Hypertension Reports</i> , 2013 , 15, 196-203	4.7	22
100	Association between urinary albumin excretion and both central and peripheral blood pressure in subjects with insulin resistance. <i>Journal of Hypertension</i> , 2013 , 31, 103-8	1.9	15
99	A review of the benefits of early treatment initiation with single-pill combinations of telmisartan with amlodipine or hydrochlorothiazide. <i>Vascular Health and Risk Management</i> , 2013 , 9, 521-8	4.4	3
98	Are there new threshold and goals in the treatment of arterial hypertension?. <i>European Journal of Clinical Investigation</i> , 2012 , 42, 914-20	4.6	5
97	Presión arterial medida en la consulta y presión arterial real. ¿Son similares?. <i>Hipertension Y Riesgo Vascular</i> , 2012 , 29, 29-30	0.5	
96	Microalbuminuria breakthrough under chronic renin-angiotensin-aldosterone system suppression. <i>Journal of Hypertension</i> , 2012 , 30, 204-9	1.9	34
95	Ambulatory blood pressure monitoring and development of cardiovascular events in high-risk patients included in the Spanish ABPM registry: the CARDIORISC Event study. <i>Journal of Hypertension</i> , 2012 , 30, 713-9	1.9	74
94	Clinical differences between resistant hypertensives and patients treated and controlled with three or less drugs. <i>Journal of Hypertension</i> , 2012 , 30, 1211-6	1.9	108

93 Hyperkalemia Risk and Treatment of Heart Failure **2012**, 81-99

92 Hyperkalemia Risk and Treatment of Heart Failure **2012**, 23-41

91 Guía de actuación para el farmacéutico comunitario en pacientes con hipertensión arterial y riesgo cardiovascular. Documento de consenso (versión resumida). *Hipertension Y Riesgo Vascular*, **2011**, 28, 169-181 0.5 3

90 Validation of a therapeutic scheme for the treatment of resistant hypertension. *Journal of the American Society of Hypertension*, **2011**, 5, 498-504 13

89 Dual-acting angiotensin receptor-neprilysin inhibition. *Current Hypertension Reports*, **2011**, 13, 74-8 4.7 10

88 Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. *Hypertension*, **2011**, 57, 898-902 8.5 547

87 Hypertension in moderate-to-severe nondiabetic CKD patients. *Advances in Chronic Kidney Disease*, **2011**, 18, 23-7 4.7 16

86 Abnormalities in ambulatory blood pressure monitoring in hypertensive patients with diabetes. *Hypertension Research*, **2011**, 34, 1185-9 4.7 35

85 A review of renal, cardiovascular and mortality endpoints in antihypertensive trials in diabetic patients. *Blood Pressure*, **2011**, 20, 322-34 1.7 6

84 New clinical concepts after the ONTARGET trial. *Expert Review of Cardiovascular Therapy*, **2011**, 9, 685-9 2.5 9

83 Diurnal blood pressure variation, risk categories and antihypertensive treatment. *Hypertension Research*, **2010**, 33, 767-71 4.7 38

82 TRENDS IN ALBUMINURIA UNDER RENIN-ANGIOTENSIN SYSTEM SUPPRESSION: HT.3.05. *Journal of Hypertension*, **2010**, 28, e446-e447 1.9 4

81 Psychological factors associated with poor hypertension control: differences in personality and stress between patients with controlled and uncontrolled hypertension. *Psychological Reports*, **2010**, 107, 923-38 1.6 16

80 Evidencias generadas por el proyecto CARDIORISC. *Hipertension Y Riesgo Vascular*, **2010**, 27, 4-8 0.5 1

79 Hipertensión arterial nocturna. *Hipertension Y Riesgo Vascular*, **2010**, 27, 26-33 0.5 2

78 Papel del personal de enfermería en el control de la hipertensión arterial y en la investigación cardiovascular. *Hipertension Y Riesgo Vascular*, **2010**, 27, 41-52 0.5

77 Long-term renal survival in malignant hypertension. *Nephrology Dialysis Transplantation*, **2010**, 25, 3266-72 56

76 Office vs. ambulatory control of hypertension in CHD patients: response to the letter "When office blood pressure measurement is not enough" by Barrios and colleagues. *International Journal of Cardiology*, **2010**, 145, 352 3.2

75	ARBs and ACEis together in the treatment of hypertension and its complications? current practical recommendations. <i>Expert Opinion on Pharmacotherapy</i> , 2010 , 11, 2619-23	4	2
74	How should we manage heart failure developing in patients already treated with angiotensin-converting enzyme inhibitors and beta-blockers for hypertension, diabetes or coronary disease?. <i>Journal of Hypertension</i> , 2010 , 28, 1595-8	1.9	10
73	Detection and treatment of resistant hypertension. <i>Current Hypertension Reports</i> , 2010 , 12, 325-30	4.7	3
72	Isolated clinic hypertension: diagnostic criteria based on 24-h blood pressure definition. <i>Journal of Hypertension</i> , 2010 , 28, 2407-13	1.9	8
71	Treatment of prehypertension in diabetes and metabolic syndrome: what are the pros?. <i>Diabetes Care</i> , 2009 , 32 Suppl 2, S284-9	14.6	11
70	Prevalence and factors associated with circadian blood pressure patterns in hypertensive patients. <i>Hypertension</i> , 2009 , 53, 466-72	8.5	270
69	Control of hypertension in coronary heart disease. <i>International Journal of Cardiology</i> , 2009 , 134, 245-7	3.2	12
68	Discrepancies between office and ambulatory blood pressure: clinical implications. <i>American Journal of Medicine</i> , 2009 , 122, 1136-41	2.4	37
67	Rosuvastatin, C-reactive protein, LDL cholesterol, and the JUPITER trial. <i>Lancet, The</i> , 2009 , 374, 26; author reply 26-7	40	3
66	Should diuretics always be included as initial antihypertensive management in early-stage CKD?. <i>Current Opinion in Nephrology and Hypertension</i> , 2009 , 18, 392-6	3.5	8
65	Kidney protection: a key target in the management of patients with diabetes. <i>Journal of Hypertension</i> , 2009 , 27, S15-8	1.9	4
64	Tolerability of high doses of lercanidipine versus high doses of other dihydropyridines in daily clinical practice: the TOLERANCE Study. <i>Cardiovascular Drug Reviews</i> , 2008 , 26, 2-9		5
63	Gender differences in office and ambulatory control of hypertension. <i>American Journal of Medicine</i> , 2008 , 121, 1078-84	2.4	26
62	Hyperkalemia risk and treatment of heart failure. <i>Heart Failure Clinics</i> , 2008 , 4, 455-64	3.3	1
61	What Do Spanish physicians believe and expect about telemedicine? Results of a Delphi-based survey. <i>Telemedicine Journal and E-Health</i> , 2008 , 14, 42-8	5.9	8
60	The importance of integrated risk management when treating patients with hypertension: benefits of angiotensin II receptor antagonist therapy. <i>Clinical and Experimental Hypertension</i> , 2008 , 30, 397-414	2.2	4
59	Clinical characteristics of isolated clinic hypertension. <i>Journal of Hypertension</i> , 2008 , 26, 438-45	1.9	37
58	New guidelines of the European Society of Hypertension. <i>Current Hypertension Reports</i> , 2008 , 10, 337-8	4.7	3

57	High doses of lercanidipine are better tolerated than other dihydropyridines in hypertensive patients with metabolic syndrome: results from the TOLERANCE study. <i>International Journal of Clinical Practice</i> , 2008 , 62, 723-8	2.9	10
56	Effectiveness of blood pressure control outside the medical setting. <i>Hypertension</i> , 2007 , 49, 62-8	8.5	142
55	Prediction of cardiovascular outcome by estimated glomerular filtration rate and estimated creatinine clearance in the high-risk hypertension population of the VALUE trial. <i>Journal of Hypertension</i> , 2007 , 25, 1473-9	1.9	56
54	Clinical trials in nephrology: success or failure. <i>Current Opinion in Nephrology and Hypertension</i> , 2007 , 16, 59-63	3.5	6
53	Ambulatory blood pressure monitoring in hypertensive patients with high cardiovascular risk: a cross-sectional analysis of a 20,000-patient database in Spain. <i>Journal of Hypertension</i> , 2007 , 25, 977-84	1.9	85
52	Are differences in calcium antagonists relevant across all stages of nephropathy or only proteinuric nephropathy?. <i>Current Opinion in Nephrology and Hypertension</i> , 2007 , 16, 422-6	3.5	3
51	Uric acid and other renal function parameters in patients with stable angina pectoris participating in the ACTION trial: impact of nifedipine GITS (gastro-intestinal therapeutic system) and relation to outcome. <i>Journal of Hypertension</i> , 2007 , 25, 1711-8	1.9	16
50	Reproducibility of the circadian blood pressure pattern in 24-h versus 48-h recordings: the Spanish Ambulatory Blood Pressure Monitoring Registry. <i>Journal of Hypertension</i> , 2007 , 25, 2406-12	1.9	45
49	Obesity, essential hypertension and renin-angiotensin system. <i>Public Health Nutrition</i> , 2007 , 10, 1151-5	3.3	65
48	Should hypertension guidelines be changed for hypertensive patients with the metabolic syndrome?. <i>Journal of Clinical Hypertension</i> , 2007 , 9, 595-600	2.3	9
47	Factores y causas de mal control y estrategias de corresponsabilidad médico-paciente en el control de la hipertensión. Resultados de los estudios COROPINA y COREVALUA del programa CORRESPONDE. <i>Hipertension</i> , 2007 , 24, 93-100		0
46	Prediabetes and cardiovascular risk in hypertensive patients. <i>Current Hypertension Reports</i> , 2006 , 8, 97-100	1.9	4
45	Predictors of the evolution of microalbuminuria. <i>Hypertension</i> , 2006 , 48, 832-3	8.5	8
44	Chronic kidney disease as a situation of high added risk in hypertensive patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2006 , 17, S136-40	12.7	12
43	Treatment of High-Risk Hypertensive Patients. <i>High Blood Pressure and Cardiovascular Prevention</i> , 2006 , 13, 13-19	2.9	
42	Antihypertensive therapy in patients with metabolic syndrome. <i>Current Opinion in Nephrology and Hypertension</i> , 2006 , 15, 493-7	3.5	10
41	Renal protection in diabetic patients: benefits of a first-line combination of perindopril-indapamide (Preterax). <i>Journal of Hypertension</i> , 2006 , 24, S9-12	1.9	2
40	Advantages of new cardiovascular risk-assessment strategies in high-risk patients with hypertension. <i>Clinical Therapeutics</i> , 2005 , 27, 1658-68	3.5	1

39	Do we need to target prediabetic hypertensive patients?. <i>Journal of Hypertension</i> , 2005 , 23, 2119-25	1.9	10
38	Minor abnormalities of renal function: a situation requiring integrated management of cardiovascular risk. <i>Fundamental and Clinical Pharmacology</i> , 2005 , 19, 429-37	3.1	8
37	Long-term renoprotective effects of standard versus high doses of telmisartan in hypertensive nondiabetic nephropathies. <i>American Journal of Kidney Diseases</i> , 2005 , 46, 1074-9	7.4	54
36	Calcium channel blockers and renal protection: insights from the latest clinical trials. <i>Journal of the American Society of Nephrology: JASN</i> , 2005 , 16 Suppl 1, S64-6	12.7	18
35	An update of irbesartan and renin-angiotensin system blockade in diabetic nephropathy. <i>Expert Opinion on Pharmacotherapy</i> , 2005 , 6, 1587-96	4	
34	Influence of chronic kidney disease development and renin-angiotensin system inhibition on cardiovascular prognosis. <i>Current Medicinal Chemistry Cardiovascular and Hematological Agents</i> , 2005 , 3, 55-60		1
33	Development of chronic kidney disease and cardiovascular prognosis in essential hypertensive patients. <i>Journal of the American Society of Nephrology: JASN</i> , 2004 , 15, 1616-22	12.7	82
32	Hope in Life and Value of blood pressure control. <i>Journal of Hypertension</i> , 2004 , 22, 2265-6	1.9	2
31	Hypertensive renal damage in metabolic syndrome is associated with glucose metabolism disturbances. <i>Journal of the American Society of Nephrology: JASN</i> , 2004 , 15 Suppl 1, S37-42	12.7	23
30	Blood pressure control and physician management of hypertension in hospital hypertension units in Spain. <i>Hypertension</i> , 2004 , 43, 1338-44	8.5	129
29	Renal endpoints in hypertension trials. <i>Clinical and Experimental Hypertension</i> , 2004 , 26, 721-6	2.2	1
28	Microalbuminuria. <i>Clinical and Experimental Hypertension</i> , 2004 , 26, 701-7	2.2	13
27	Effect of proteinuria and glomerular filtration rate on cardiovascular risk in essential hypertension. <i>Kidney International</i> , 2004 , S45-9	9.9	34
26	On the importance of estimating renal function for cardiovascular risk assessment. <i>Journal of Hypertension</i> , 2004 , 22, 1635-9	1.9	16
25	Intervention at lower blood pressure levels to achieve target goals in type 2 diabetes: PRADID (PRESiñ Arterial en Diabéticos tipo Dos) study. <i>Journal of Hypertension</i> , 2004 , 22, 217-22	1.9	14
24	Cerebrovascular protection and antihypertensive therapy. <i>Current Opinion in Nephrology and Hypertension</i> , 2004 , 13, 507-12	3.5	3
23	Development of chronic kidney disease in essential hypertension during long-term therapy. <i>Current Opinion in Nephrology and Hypertension</i> , 2004 , 13, 495-500	3.5	
22	Chronic kidney disease and global cardiovascular risk in essential hypertension. <i>Minerva Medica</i> , 2004 , 95, 375-83	2.2	2

21	Renal participation in cardiovascular risk in essential hypertension. <i>Expert Review of Cardiovascular Therapy</i> , 2003 , 1, 309-15	2.5	2
20	Doxazosin GITS versus hydrochlorothiazide as add-on therapy in patients with uncontrolled hypertension. <i>Blood Pressure</i> , 2003 , 2, 16-21	1.7	10
19	How to titrate ACE inhibitors and angiotensin receptor blockers in renal patients: according to blood pressure or proteinuria?. <i>Current Hypertension Reports</i> , 2003 , 5, 426-9	4.7	15
18	Losartan and other angiotensin II antagonists for nephropathy in type 2 diabetes mellitus: a review of the clinical trial evidence. <i>Clinical Therapeutics</i> , 2003 , 25, 3044-64	3.5	30
17	Hyperuricemia, low urine urate excretion and target organ damage in arterial hypertension. <i>Blood Pressure</i> , 2003 , 12, 277-83	1.7	23
16	ACE inhibition or angiotensin receptor blockade: which should we use in diabetic patients?. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2003 , 4, 74-9	3	4
15	Combination is better than monotherapy with ACE inhibitor or angiotensin receptor antagonist at recommended doses. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2003 , 4, 43-7	3	43
14	Proteinuria: an underappreciated risk factor in cardiovascular disease. <i>Current Cardiology Reports</i> , 2002 , 4, 458-62	4.2	20
13	Renal protection by antihypertensive therapy. <i>Current Hypertension Reports</i> , 2002 , 4, 324-8	4.7	4
12	Conservative versus immunosuppressive treatment of patients with idiopathic membranous nephropathy. <i>Kidney International</i> , 2002 , 61, 219-27	9.9	56
11	Cardiovascular therapy in patients with renal insufficiency. <i>Cardiovascular Drugs and Therapy</i> , 2002 , 16, 497-501	3.9	
10	Factors influencing the systolic blood pressure response to drug therapy. <i>Journal of Clinical Hypertension</i> , 2002 , 4, 35-40	2.3	14
9	How relevant and frequent is the presence of mild renal insufficiency in essential hypertension?. <i>Journal of Clinical Hypertension</i> , 2002 , 4, 332-6	2.3	31
8	ACE inhibitors and appearance of renal events in hypertensive nephrosclerosis. <i>Hypertension</i> , 2001 , 38, 645-9	8.5	33
7	A prospective comparison of four antihypertensive agents in daily clinical practice. <i>Journal of Clinical Hypertension</i> , 2001 , 3, 139-44	2.3	2
6	A random comparison of fosinopril and nifedipine GITS in patients with primary renal disease. <i>Journal of Hypertension</i> , 2001 , 19, 1871-6	1.9	60
5	Comparative study of home and office blood pressure in hypertensive patients treated with enalapril/HCTZ 20/6 mg: the ESPADA study. <i>Blood Pressure</i> , 2000 , 9, 355-62	1.7	6
4	Mycophenolate mofetil slows the decline of renal function in patients with biopsy-proven chronic rejection: a collaborative pilot study. <i>Transplantation Proceedings</i> , 1999 , 31, 2267-9	1.1	7

3	The kidney in heart failure: role of angiotensin II. <i>Current Opinion in Nephrology and Hypertension</i> , 1999 , 8, 153-156	3.5	3
2	Influence of hepatitis C virus infection on FK 506 blood levels in renal transplant patients. <i>Transplantation Proceedings</i> , 1998 , 30, 1264-5	1.1	14
1	Antiproteinuric effect of angiotensin-converting enzyme inhibition and C5b-9 urinary excretion in membranous glomerulonephritis. <i>Nephrology Dialysis Transplantation</i> , 1997 , 12, 2576-9	4.3	5